The present invention relates to a method and system for facilitating hemostasis of a blood vessel.
Numerous arterial puncture closure devices are known in the prior art. These include many mechanisms, such as plugs, sutures, intra-vascular structures and more. While these prior art devices vary in size and theory, they all require placement of distinct closure devices through a procedural sheath, sheath exchanges, or sheath removal prior to placement. By their very nature, these devices represent a separate procedure for access site closure after access site establishment/maintenance. The decision to use these devices is often based upon the instant availability of the device and competing demand for the doctor's time at the moment of sheath removal.
An additional challenge of puncture closure devices comes when they are deployed many hours after access has been established. In these cases, time and additional access site manipulation contribute to potential infection.
What is needed is a single device which establishes and maintains access to a puncture site, and closes the access site upon the completion of a procedure. In this way, the closure of the puncture site could become a standard of care, not subject to device availability, competing demand for doctor time, or site infection due to delayed deployment.
Accordingly, it would be desirable to provide a method and system that enable the user to access a blood vessel with a sheath that also incorporates a means for access site closure. Furthermore, upon completion of the interventional procedure, the closure device is deployed to close the puncture and the sheath is removed.
The present invention provides an improved method and system for facilitating hemostasis of a blood vessel puncture.
In accordance with one aspect of the present invention, a method of facilitating hemostasis of a blood vessel puncture includes the steps of inserting a tubular device into a puncture in a blood vessel to establish access to the blood vessel; providing a vessel closure system around the tubular device; introducing a hemostasis promoting material into a space between the tubular device and vessel closure system; and delivering the hemostatic material adjacent to the puncture to facilitate hemostasis of the puncture.
In accordance with a further aspect of the present invention, a method of facilitating hemostasis of a blood vessel puncture, the method includes inserting a procedural access sheath through a tissue tract and into a puncture in a blood vessel; providing a vessel closure system around the access sheath and at least partially in the issue tract; and performing a vascular procedure with the vessel closure system in the tissue tract.
In accordance with another aspect of the present invention, a system for facilitating hemostasis of a blood vessel puncture, the system including a delivery cannula configured to be received around an access sheath; a hemostasis promoting material within the delivery cannula for facilitating hemostasis of a blood vessel puncture when delivered adjacent to the puncture; a proximal stop for preventing proximal motion of the hemostasis promoting material within the delivery cannula when the access sheath is withdrawn proximally from the delivery cannula; and a pusher for delivering the sponge material from the delivery cannula.
The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
a is a perspective view of a first embodiment of a delivery cannula according to the present invention positioned for delivery of a hemostatic promoting material;
b is a perspective view of the delivery cannula of
c is a perspective view of the delivery cannula of
d is a perspective view of an alternative embodiment of a delivery cannula with a side staging chamber;
e is a perspective view of the delivery cannula of
a is a perspective view of a delivery cannula according to an alternative embodiment;
b is a perspective view of a delivery cannula according to an alternative embodiment;
a is a perspective view of a delivery cannula according to an alternative embodiment;
b is a perspective view of a delivery cannula according to an another embodiment;
a is a perspective view of a delivery cannula according to an another embodiment; and
b is a perspective view of a delivery cannula according to an alternative embodiment.
The present invention provides an access system that enables the user to access a blood vessel with a sheath that also incorporates a means for performing site closure. Upon completion of the interventional procedure, the closure device is deployed to close the puncture and the sheath is removed.
As shown in
The delivery cannula 10 as shown in
While the hemostatic material space 26 described herein is coaxial, it can be appreciated that many other configurations are possible. The hemostatic material space 26 is defined by the outside of the access sheath 20 and the inside of the delivery cannula 10 and may be continuous, discontinuous, symmetrical, or nonsymmetrical.
In one preferred embodiment as shown in
In another preferred embodiment, as shown in
The system can then be placed much like an ordinary access sheath 20 as shown in
Bleed-back 62 is facilitated by providing a dilator 70 within the access sheath 20 that fits closely over the guidewire 54 at its distal end 74 such that it substantially prevents blood from entering the dilator 70. Further, the dilator 70 fits closely within the distal access sheath 20 such that it substantially prevents blood from entering the access sheath. In this way, blood is restricted from entering the access sheath 20 until the bleed-back hole 60 enters the blood vessel 58. Blood entering the bleed-back hole 60 might then exit the patient through a number of paths.
If the access sheath 20 was provided with a seal at its proximal end 22, the blood might enter a hole in the dilator 70 and then exit the proximal end 72 of the dilator 70. Alternatively, blood could flow between the dilator 70 and access sheath 20 to an exit in the introduction port 76 and stop-cock 78 as shown in
In operation, the access systems of the present invention are used as follows. The interventional procedure is conducted as usual with the delivery cannula 10 and hemostatic material 30 in place during the procedure. At the end of the interventional procedure, the access sheath 20 portion of the system is detached from the delivery cannula 10 and fully withdrawn while the delivery cannula 10 and proximal stop 40 remain stationary as shown in
The proximal stop 40 is then removed from the delivery cannula 10 and a pusher 80 having an outside diameter just smaller than the inside diameter of the delivery cannula 10 is placed over the guidewire 54 (if present) and advanced until it contacts the proximal portion of hemostatic material 30. As shown in
In one preferred embodiment, the pusher 80 is held stationary while the delivery cannula 10 is withdrawn. It is also understood that the pusher 80 can be advanced while the delivery cannula 10 is held stationary. It is further understood that any combination of these techniques can result in delivery of hemostatic material 30. After delivering hemostatic material 30 into the desired site, the guidewire 54 (if present) and the pusher 80 and cannula 10 are removed from the puncture tract.
In an alternative embodiment, as shown in
A pusher 80 shown in
In an alternative embodiment, as shown in
As shown in
In still another embodiment shown in
As shown in
Other means of positioning the hemostatic material within the system include placing the hemostatic material within the distal lumen of the delivery cannula 10 and then passing the access sheath 20 through it.
In another preferred embodiment the hemostatic promoting material 30 is placed in the cannula by placing a hydrated sponge within the distal end 14 of the delivery cannula 10. The distal end 24 of the access sheath 20 with a stylet or obturator placed within it is then advanced into the proximal end 12 of the delivery cannula 10 and through the sponge until the distal access sheath 20 protrudes beyond the distal end 14 of the delivery cannula 10. The stylet or obturator is then removed to ready the system for placement into an access site.
The absorbable sponge material can be absorbed by the body in a period of time between several days and several months depending on the absorbable sponge material used. A pledget formed of commercially available Gelfoam material will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be engineered to provide different rates of absorption. For example, Gelfoam can be designed to be absorbed at different rates by varying the degree of crosslinking. Preferably, the pledget is designed to be absorbed in less than one month.
Although the invention is primarily intended for delivery of absorbable sponge, non-absorbable sponge may also be delivered with the devices, systems, and methods of the present invention. A non-absorbable sponge may be desirable where it will be necessary to locate the blood vessel puncture after the procedure.
While an amorphous or discontinuous sponge structure may be used in the present invention, a continuous structure of the delivered absorbable sponge pledget provides more secure and reliable placement of a plug of material against the blood vessel puncture than a paste or liquid. The continuous sponge structure can even facilitate partial withdrawal, removal, or movement of the ejected pledget.
The absorbable sponge material can be hydrated with a clotting agent such as thrombin, a contrast agent, another beneficial agent, a combination of agents, or the like. Alternatively, the pledget material itself may contain an agent such as a clotting agent, a contrast agent, another beneficial agent, a combination of agents, or the like.
The absorbable sponge pledget may be presoaked with a beneficial agent such as thrombin for delivery of the beneficial agent to the punctured blood vessel. Alternatively, the pledget may be hydrated with a beneficial liquid agent used as the hydrating fluid within a syringe. Further, the beneficial agent may be delivered to the pledget after the pledget is ejected at the blood vessel puncture site through the lumen of the pusher 80, through the delivery cannula 10, through the access sheath 20 or through the dilator 70.
Because the amount of subcutaneous fat and tissue between the skin 64 and the blood vessel wall 58 varies between patients from approximately 0.5 cm to 15 cm or more the system may be provided in different lengths for use in different patients. The pledget size and shape may also be varied for different patients. The absorbable sponge material should form a complete plug over the puncture site without expanding into the blood vessel or exiting the skin of the patient. In some instances where the amount of subcutaneous tissue is great it may be desirable to deliver multiple pledgets in spaced apart positions along the tract leading to the puncture site.
The particular size and shape of the access system may vary depending on the size of the access site, amount of subcutaneous tissue, and the size of pledget to be delivered. According to one example of the present invention, a pledget is formed from a rectangular piece of pre-compressed Gelfoam approximately 2 by 3 cm with a thickness of 0.15 cm. The Gelfoam is rolled or folded into a pledget having a length of approximately 3 cm. An introducer for delivery of this pledget to a patient with an average amount of subcutaneous tissue has a staging chamber length of about 2.5 to 6 cm, preferably approximately 3 cm, a staging chamber inner diameter of about 0.12 to 1.5 cm, preferably about 0.3 cm to about 0.6 cm, and a delivery chamber which is typically longer than the staging chamber and has an inner diameter smaller than that of the staging chamber of about 1 cm or less, preferably approximately 0.33 cm or less. The particular length of the delivery chamber depends on both the subcutaneous tissue depth of the patient and the linear expansion of the pledget as it moves from the staging chamber to the delivery chamber. An angle made by a wall of the tapered section 38 with a longitudinal axis of the adaptor may vary from about 5.degree. to 90.degree., but is preferably between about 30.degree. and 60.degree., more preferably approximately 45.degree.. The tapered section 38 is illustrated with a substantially planar interior surface, when shown in cross section. However, the tapered section may also have a convex or concave surface in cross-section. This example of pledget and introducer configurations is merely exemplary of the present invention.
In addition, the hemostatic promoting material 30 may be inserted into the cannula in a dry form and hydrated in the cannula. Alternatively, the hemostatic material may be hydrated prior to staging in the cannula, hydrated after delivery or any combination thereof.
While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
This application is a continuation of U.S. patent application Ser. No. 10/754,824, filed Jan. 9, 2004, now U.S. Pat. No. 7,621,936, which is a continuation of U.S. patent application Ser. No. 09/904,445, filed Jul. 11, 2001, now abandoned, which claims priority under 35 U.S.C. §119 to provisional U.S. Patent Application Ser. No. 60/218,431, filed Jul. 14, 2000. These applications are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
581235 | Kenyon | Apr 1897 | A |
1578517 | Hein | Mar 1926 | A |
2086580 | Shirley | Jul 1937 | A |
2465357 | Correll | Mar 1949 | A |
2492458 | Bering | Dec 1949 | A |
2507244 | Correll | May 1950 | A |
2558395 | Studer | Jun 1951 | A |
2597011 | MacMasters et al. | May 1952 | A |
2680442 | Linzmayer | Jun 1954 | A |
2761446 | Reed | Sep 1956 | A |
2814294 | Figge | Nov 1957 | A |
2824092 | Thompson | Feb 1958 | A |
2899362 | Sieger et al. | Aug 1959 | A |
3157524 | Artandi | Nov 1964 | A |
3724465 | Duchane | Apr 1973 | A |
4000741 | Binard et al. | Jan 1977 | A |
4323072 | Rosenbluth et al. | Apr 1982 | A |
4340066 | Shah | Jul 1982 | A |
4390018 | Zukowski | Jun 1983 | A |
4405314 | Cope | Sep 1983 | A |
4515637 | Cioca | May 1985 | A |
4587969 | Gillis | May 1986 | A |
4588395 | Lemelson | May 1986 | A |
4619261 | Guerriero | Oct 1986 | A |
4619913 | Luck et al. | Oct 1986 | A |
4645488 | Matukas | Feb 1987 | A |
4744364 | Kensey | May 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4829994 | Kurth | May 1989 | A |
4850960 | Grayzel | Jul 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4900303 | Lemelson | Feb 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4936835 | Haaga | Jun 1990 | A |
4950234 | Fujioka et al. | Aug 1990 | A |
5007895 | Burnett | Apr 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5053046 | Janese | Oct 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5080655 | Haaga | Jan 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5163904 | Lampropoulos et al. | Nov 1992 | A |
5167624 | Butler et al. | Dec 1992 | A |
5192300 | Fowler | Mar 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5195988 | Haaga | Mar 1993 | A |
5206028 | Li | Apr 1993 | A |
5220926 | Jones | Jun 1993 | A |
5221259 | Weldon et al. | Jun 1993 | A |
5275616 | Fowler | Jan 1994 | A |
5290310 | Makower et al. | Mar 1994 | A |
5310407 | Casale | May 1994 | A |
5325857 | Nabai et al. | Jul 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5366480 | Corriveau | Nov 1994 | A |
5383896 | Gershony et al. | Jan 1995 | A |
5383899 | Hammerslag | Jan 1995 | A |
5388588 | Nabai et al. | Feb 1995 | A |
5391183 | Janzen et al. | Feb 1995 | A |
5419765 | Weldon et al. | May 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5437631 | Janzen | Aug 1995 | A |
5467780 | Nabai et al. | Nov 1995 | A |
5478352 | Fowler | Dec 1995 | A |
5479936 | Nabai et al. | Jan 1996 | A |
5486195 | Myers et al. | Jan 1996 | A |
5522850 | Yomtov et al. | Jun 1996 | A |
5526822 | Burbank et al. | Jun 1996 | A |
5529577 | Hammerslag | Jun 1996 | A |
5540715 | Katsaros et al. | Jul 1996 | A |
5542914 | Van Iten | Aug 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5558853 | Quay | Sep 1996 | A |
5591204 | Janzen et al. | Jan 1997 | A |
5591205 | Fowler | Jan 1997 | A |
5601602 | Fowler | Feb 1997 | A |
5645566 | Brenneman et al. | Jul 1997 | A |
5649547 | Ritchart et al. | Jul 1997 | A |
5653730 | Hammerslag | Aug 1997 | A |
5665107 | Hammerslag | Sep 1997 | A |
5676689 | Kensey et al. | Oct 1997 | A |
5681279 | Roper et al. | Oct 1997 | A |
5716375 | Fowler | Feb 1998 | A |
5716394 | Bruchman et al. | Feb 1998 | A |
5725498 | Janzen et al. | Mar 1998 | A |
5728122 | Leschinsky et al. | Mar 1998 | A |
5741223 | Janzen et al. | Apr 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5775333 | Burbank et al. | Jul 1998 | A |
5810806 | Ritchart et al. | Sep 1998 | A |
5830130 | Janzen et al. | Nov 1998 | A |
5902310 | Foerster et al. | May 1999 | A |
5928266 | Kontos | Jul 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6033427 | Lee | Mar 2000 | A |
6071301 | Cragg et al. | Jun 2000 | A |
6162192 | Cragg et al. | Dec 2000 | A |
Number | Date | Country | |
---|---|---|---|
20100049245 A1 | Feb 2010 | US |
Number | Date | Country | |
---|---|---|---|
60218431 | Jul 2000 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10754824 | Jan 2004 | US |
Child | 12606526 | US | |
Parent | 09904445 | Jul 2001 | US |
Child | 10754824 | US |